Immunovant (IMVT) Director Atul Pande Exercises Options, Sells 1,500 Shares

What Happened
Atul Pande, a director of Immunovant, exercised options to acquire 1,500 common shares at $8.43 per share (cost $12,645) and immediately sold 1,500 shares in an open-market transaction at $43.27 per share for gross proceeds of $64,905. The exercise is reported with code M (exercise/conversion of a derivative). One additional M-line shows a disposition of 1,500 shares at $0.00 (see footnote explanation below).

Key Details

• Transaction date: August 28, 2026. Sale price: $43.27; Exercise price: $8.43.
• Shares exercised/acquired: 1,500 (cost $12,645). Shares sold/disposed: 1,500 (gross proceeds $64,905). Net proceeds (sale minus exercise cost) ≈ $52,260 before taxes/fees.
• Footnotes: F1 — the sale was made pursuant to a Rule 10b5-1 trading plan adopted Dec 26, 2025; F2 — the reported option award was fully vested.
• Filing status: Reported on Aug 28, 2026 (no late filing indicated in the provided data).
• Shares owned after transaction: Not specified in the provided summary of the filing.
• Transaction codes: M = exercise/conversion of derivative (option). The reported disposition at $0.00 likely reflects an administrative conversion/settlement related to the option exercise (e.g., internal settlement or withholding), as noted in the filing.

Context
This was an option exercise immediately followed by a sale of the same shares and was executed under a pre-established 10b5-1 plan (a scheduled trading plan). For retail investors, scheduled sales under 10b5-1 plans are typically routine and do not necessarily indicate a change in the insider’s private view of the company.